Guidelines roundup for obesity

Obesity treatment starts with a simple screening tool, not a diagnosis by itself. Body mass index is a height-and-weight ratio, and the Centers for Disease Control and Prevention says it is a screening measure that has to be interpreted alongside other health factors. (cdc.gov) That distinction is why current guidelines do not treat obesity like a math problem with one cutoff and one answer. The American Association of Clinical Endocrinology built its guidance around screening, diagnosis, clinical evaluation, treatment options, therapy selection, and treatment goals rather than a single number on a chart. (aace.com) The new American Journal of Managed Care review pulls together those guidelines and lands on a blunt point: the standard of care is evidence-based treatment, not detoxes, “metabolism resets,” or other fad plans. The review says the American College of Cardiology, American Heart Association, and The Obesity Society guideline and the American Association of Clinical Endocrinology guideline still anchor obesity care. (ajmc.com) The first line of treatment is still lifestyle therapy, but guidelines mean more than “eat less and move more.” The United States Preventive Services Task Force recommends intensive behavioral interventions for adults with obesity, which usually means structured coaching on food, activity, and habits over repeated visits rather than a one-page handout. (uspreventiveservicestaskforce.org) When lifestyle treatment is not enough, the guidelines move to medicines instead of pretending willpower failed. The American Gastroenterological Association recommends adding anti-obesity medication for adults with obesity, or overweight with weight-related complications, after an inadequate response to lifestyle intervention alone. (gastro.org) Those medicine recommendations are now shaped by newer drugs with stronger results than the older options many doctors trained on. The same American Gastroenterological Association guideline specifically suggests semaglutide 2.4 milligrams and also lists liraglutide, phentermine-topiramate extended release, and naltrexone-bupropion extended release, while suggesting against orlistat. (gastro.org) The diabetes guidelines now treat weight loss as a primary target, not a side quest, for many patients with type 2 diabetes. The American Diabetes Association’s 2025 standards say weight management should be a primary goal of treatment alongside blood sugar management in people with type 2 diabetes and overweight or obesity. (diabetesjournals.org) Drug treatment is also no longer framed only as a way to change the scale. In March 2024, the Food and Drug Administration approved semaglutide, sold as Wegovy, to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight. (fda.gov) Surgery remains in the guidelines because it produces the largest and most durable weight loss for severe obesity. The American Society for Metabolic and Bariatric Surgery says metabolic and bariatric surgery is recommended for people with a body mass index of 35 or higher regardless of coexisting conditions, and for people with type 2 diabetes and a body mass index of 30 or higher. (asmbs.org) One newer thread across these guidelines is that obesity is treated as a chronic disease that needs long-term follow-up, like high blood pressure or asthma. The American Association of Clinical Endocrinology’s more recent obesity materials also add a separate focus on stigma and bias, which means care is supposed to address health risk without treating patients like they caused a moral failure. (aace.com) That is what the AJMC roundup is really capturing in one place: modern obesity care is now a ladder. It starts with screening and structured behavior change, steps up to medication when needed, includes surgery for the right patients, and keeps the focus on proven outcomes instead of fad promises. (ajmc.com)